Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) have earned a consensus rating of “Buy” from the fifteen ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $13.25.
A number of equities analysts have issued reports on the stock. ValuEngine cut shares of CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 10th. Cantor Fitzgerald set a $20.00 target price on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a report on Wednesday, September 18th. Zacks Investment Research raised shares of CymaBay Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 target price on the stock in a report on Tuesday, October 8th. Evercore ISI reissued a “buy” rating and issued a $15.00 target price on shares of CymaBay Therapeutics in a report on Wednesday, August 14th. Finally, BidaskClub cut shares of CymaBay Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 30th.
In other CymaBay Therapeutics news, CEO Sujal Shah purchased 5,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were bought at an average price of $5.53 per share, with a total value of $27,650.00. Following the completion of the acquisition, the chief executive officer now owns 111,900 shares in the company, valued at approximately $618,807. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have bought 11,900 shares of company stock worth $59,600. Corporate insiders own 4.20% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new stake in shares of CymaBay Therapeutics during the second quarter valued at approximately $303,000. Bailard Inc. raised its holdings in shares of CymaBay Therapeutics by 43.5% during the second quarter. Bailard Inc. now owns 308,700 shares of the biopharmaceutical company’s stock valued at $2,210,000 after buying an additional 93,600 shares during the last quarter. University of Notre Dame DU Lac bought a new stake in shares of CymaBay Therapeutics during the second quarter valued at approximately $2,043,000. Aperio Group LLC bought a new stake in shares of CymaBay Therapeutics during the second quarter valued at approximately $104,000. Finally, Marshall Wace LLP raised its holdings in shares of CymaBay Therapeutics by 17.0% during the first quarter. Marshall Wace LLP now owns 63,589 shares of the biopharmaceutical company’s stock valued at $844,000 after buying an additional 9,231 shares during the last quarter. 98.60% of the stock is currently owned by institutional investors.
Shares of NASDAQ CBAY opened at $5.04 on Wednesday. The company has a quick ratio of 16.20, a current ratio of 16.20 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $5.31 and its two-hundred day moving average price is $8.17. CymaBay Therapeutics has a 52-week low of $4.23 and a 52-week high of $14.00. The stock has a market capitalization of $326.33 million, a P/E ratio of -4.00 and a beta of 1.32.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. As a group, equities research analysts expect that CymaBay Therapeutics will post -1.47 earnings per share for the current year.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
See Also: What is the significance of the death cross?
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.